FutureChem Co.Ltd - Asset Resilience Ratio
FutureChem Co.Ltd (220100) has an Asset Resilience Ratio of 24.16% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See FutureChem Co.Ltd (220100) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how FutureChem Co.Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of FutureChem Co.Ltd.
Liquid Assets Composition Over Time
This chart breaks down FutureChem Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of FutureChem Co.Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩16.84 Billion | 24.16% |
| Total Liquid Assets | ₩16.84 Billion | 24.16% |
Asset Resilience Insights
- Good Liquidity Position: FutureChem Co.Ltd maintains a healthy 24.16% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
FutureChem Co.Ltd Industry Peers by Asset Resilience Ratio
Compare FutureChem Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for FutureChem Co.Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for FutureChem Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.78% | ₩22.20 Billion ≈ $15.04 Million |
₩74.53 Billion ≈ $50.51 Million |
-7.06pp |
| 2024-12-31 | 36.84% | ₩27.42 Billion ≈ $18.58 Million |
₩74.42 Billion ≈ $50.43 Million |
+13.02pp |
| 2023-12-31 | 23.82% | ₩17.35 Billion ≈ $11.76 Million |
₩72.83 Billion ≈ $49.36 Million |
-18.50pp |
| 2022-12-31 | 42.31% | ₩37.54 Billion ≈ $25.44 Million |
₩88.72 Billion ≈ $60.12 Million |
+4.64pp |
| 2021-12-31 | 37.67% | ₩29.06 Billion ≈ $19.69 Million |
₩77.14 Billion ≈ $52.27 Million |
-14.26pp |
| 2020-12-31 | 51.93% | ₩42.82 Billion ≈ $29.02 Million |
₩82.46 Billion ≈ $55.88 Million |
+48.14pp |
| 2019-12-31 | 3.79% | ₩2.40 Billion ≈ $1.62 Million |
₩63.21 Billion ≈ $42.84 Million |
-55.97pp |
| 2018-12-31 | 59.76% | ₩38.28 Billion ≈ $25.94 Million |
₩64.05 Billion ≈ $43.40 Million |
+28.78pp |
| 2017-12-31 | 30.98% | ₩11.15 Billion ≈ $7.56 Million |
₩36.00 Billion ≈ $24.40 Million |
+12.86pp |
| 2016-12-31 | 18.12% | ₩6.00 Billion ≈ $4.07 Million |
₩33.11 Billion ≈ $22.44 Million |
-- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more